Last edition
News about "Eli Lilly breast cancer drug"
US FDA Approves Inluriyo in Combination with Verzenio
US FDA has approved Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
Eli Lilly Breast Cancer Drug | 21/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members